New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials

Further Publications Dermatology

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials

J Eur Acad Dermatol Venereol

Zouboulis CC, Kyrgidis A, Alavi A, Jemec GBE, Martorell A, Marzano AV, van der Zee HH, Wozniak MB, Martinez AL, Kasparek T, Bachhuber T, Ortmann CE, Lobach I, Thomas N, Ravichandran S, Tzellos T

doi: 10.1111/jdv.20369

Further Publications Dermatology

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials

J Eur Acad Dermatol Venereol

Calabrese L, Cartocci A, Rubegni P, French LE, Kendziora B

doi: 10.1111/jdv.20617

Alopecia Areata

Sustained hair regrowth with continued ritlecitinib treatment through Week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b/3 trial

J Am Acad Dermatol

Piliang M, Lynde C, King B, Mirmirani P, Sinclair R, Senna M, Forman S, Bordone L, De La Cueva Dobao P, Wolk R, Zwillich SH, Tran H, Wajsbrot D, Ahmed HM, Takiya L

doi: 10.1016/j.jaad.2024.09.064

Rheumatoid Arthritis

A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48)

Arthritis Res Ther

Leng X, Leszczyński P, Jeka S, Liu S, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Mitroiu M, Addison J, Rezk MF, Zeng X

doi: 10.1186/s13075-024-03375-w

Further Publications Dermatology

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Lancet

Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, Garg A, Gottlieb AB, Szepietowski JC, Bechara FG, Giamarellos-Bourboulis EJ, Fujita H, Rolleri R, Joshi P, Dokhe P, Muller E, Peterson L, Madden C, Bari M, Zouboulis CC

doi: 10.1016/S0140-6736(24)00101-6

Psoriatic Arthritis

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Ann Rheum Dis

Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie A

doi: 10.1136/ard-2024-226150

Psoriatic Arthritis

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Ann Rheum Dis

Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie A

doi: 10.1136/ard-2024-226150

Further Publications Dermatology

A qualitative interview study exploring patient views and experiences of treatment for hidradenitis suppurativa in the UK

Br J Dermatol

Howells L, Leighton P, Thomas KS, Collier F, Gibbons A, Harris C, Hood K, Riaz M, Rodrigues J, Stanton H, Thomas-Jones E, Ingram JR

doi: 10.1093/bjd/ljaf046

Atopic Dermatitis

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials

Adv Ther

Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D, Metz M, Chen Z, Hagen S, Bastian M

doi: 10.1007/s12325-025-03124-8

Related content

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials

Sustained hair regrowth with continued ritlecitinib treatment through Week 48 in patients with alopecia areata with or without early target responses: post hoc analysis of the ALLEGRO phase 2b/3 trial

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

A qualitative interview study exploring patient views and experiences of treatment for hidradenitis suppurativa in the UK

Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials